Loading...
XPAR
AB
Market cap92mUSD
Dec 04, Last price  
1.20EUR
1D
3.45%
1Q
0.00%
Jan 2017
-91.23%
IPO
-90.54%
Name

AB Science SA

Chart & Performance

D1W1MN
XPAR:AB chart
P/E
—
P/S
74.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.79%
Rev. gr., 5y
-7.36%
Revenues
1m
+10.52%
316,000917,0001,104,0001,340,0001,933,0002,099,0002,284,0001,508,0001,739,0001,701,0001,571,0001,583,0001,607,000958,000970,0001,072,000
Net income
-8m
L-22.06%
-8,110,000-9,489,000-9,651,000-10,985,000-14,611,000-16,112,000-26,716,000-27,696,000-27,122,000-26,061,000-21,748,000-15,045,000-14,463,000-13,615,000-10,048,000-7,831,000
CFO
525k
P
-7,766,000-7,863,000-8,320,000-6,211,000-12,835,000-14,158,000-23,155,000-33,520,000-22,896,000-26,792,000-15,156,000-13,511,000-17,178,000-17,471,000-16,871,000525,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
URL
https://www.ab-science.com/
IPO date
Apr 21, 2010
Employees
103
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT